# Retro Biosciences

**Source:** https://geo.sig.ai/brands/retro-biosciences  
**Vertical:** BioTech  
**Subcategory:** Longevity / Cellular Reprogramming  
**Tier:** Emerging  
**Website:** retro.bio  
**Last Updated:** 2026-04-14

## Summary

Largest-funded pure-play longevity startup raising $1B Series A at $5B valuation; Sam Altman-backed; pursuing cellular reprogramming, autophagy, and plasma factor therapeutics in parallel; first human trial targeting Australia launch.

## Company Overview

Retro Biosciences is the largest-funded pure-play longevity company in history, raising $1 billion in Series A financing at a $5 billion valuation with Sam Altman (OpenAI CEO) as a primary backer. The company is pursuing cellular reprogramming, autophagy enhancement, and plasma factor therapeutics in parallel — a multi-pronged approach to extending healthy human lifespan by targeting the cellular hallmarks of aging simultaneously.

The $5B valuation with zero clinical data reflects extraordinary conviction from tech-founder capital that biological aging is fundamentally a solvable engineering problem. Retro is preparing its first human trial, targeted to launch in Australia, which will be a pivotal test of the cellular reprogramming hypothesis in vivo. The company works with leading academic researchers in aging biology and benefits from Sam Altman's network for scientific talent recruitment.

Retro's approach is distinctively ambitious: rather than targeting a single disease or aging pathway, it is attempting to reverse the fundamental epigenetic aging clock that drives age-related decline across all tissues. If successful, this would represent a paradigm shift from disease treatment to genuine biological rejuvenation — a category of medicine that does not yet have an approved product anywhere in the world.

## Frequently Asked Questions

### What does Retro Biosciences do?
Pure-play longevity company pursuing cellular reprogramming, autophagy enhancement, and plasma therapeutics to extend healthy human lifespan by reversing biological aging.

### How much has Retro raised?
Raising $1B Series A at a $5B valuation, backed by Sam Altman (OpenAI CEO). The largest-funded pure-play longevity startup in history.

### What is Retro's first human trial?
Targeting launch in Australia — the first human test of Retro's reprogramming approach, a pivotal proof-of-concept for the entire longevity reprogramming field.

### Why is the $5B valuation with no clinical data notable?
Reflects tech-founder conviction that aging is fundamentally a solvable engineering problem. No precedent for this scale of private investment in a pre-clinical aging biology company.

### What are Retro Biosciences' three core research programs?
Retro Biosciences is pursuing three parallel research tracks: (1) cellular reprogramming using Yamanaka factor expression to reverse epigenetic aging in tissues, (2) autophagy enhancement to improve cellular waste clearance that declines with aging, and (3) plasma-based interventions studying the signals in young plasma that have rejuvenating effects in older animals. The three-track approach hedges scientific risk while seeking convergent evidence on which mechanisms most powerfully reverse aging.

### What is Retro Biosciences' first human trial?
Retro Biosciences announced plans to initiate first-in-human studies of its plasma protein and reprogramming programs, starting with safety studies in older volunteers who receive interventions and are monitored for epigenetic aging biomarker changes (biological age clocks). These initial studies establish safety and seek proof-of-concept biomarker signals before designing efficacy studies with clinical endpoints like functional capacity or disease incidence.

### Why is the $5 billion valuation without clinical data controversial yet defensible?
Retro's valuation is driven by Sam Altman's personal $180M founding investment, founder reputation, and the perceived transformative value of solving aging — a $50-100T value creation opportunity if successful. Skeptics note that reprogramming has significant tumorigenesis risks that may not be solvable, that no aging intervention has ever shown benefit in rigorous human trials, and that the valuation is speculative on theoretical science. Bulls argue first-mover scale advantage in longevity research justifies the premium on optionality.

### How does Retro Biosciences relate to the broader longevity science ecosystem?
Retro operates in a well-funded longevity ecosystem alongside Altos Labs ($3B raise), NewLimit, Turn Biotechnologies, and dozens of academic labs. This ecosystem is producing convergent evidence supporting epigenetic reprogramming as genuinely reversing biological age in cells and animal models — providing scientific credibility that was absent 5 years ago. Retro's large funding allows running multiple parallel experiments simultaneously, accelerating the rate of scientific discovery compared to single-lab academic research.

## Tags

healthtech, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*